Merck's Capvaxive gears up to challenge Pfizer's dominant Prevnar with CDC panel backing

[cafead]

via After scoring approval as the world’s first pneumococcal disease vaccine made specifically for adults earlier this month, Merck’s Capvaxive passed the next test in its bid to take on Pfizer and its dominant Prevnar franchise.

article source